Design and characterization of an HIV-specific ribonuclease zymogen

AIDS Research and Human Retroviruses

Volumn 24, Issue 11, 2008, Pages 1357-1363

  Turcotte, Rebecca F ^a   Raines, Ronald T ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME PRECURSOR; RANPIRNASE; RIBONUCLEASE; RIBONUCLEASE A; VIRUS ENZYME; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PANCREATIC RIBONUCLEASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; ANIMAL; BOVINAE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; ENZYME SPECIFICITY; ENZYMOLOGY; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; K562 CELL LINE;

ANIMALS; ANTI-HIV AGENTS; CATTLE; DRUG DESIGN; ENZYME ACTIVATION; ENZYME PRECURSORS; HIV INFECTIONS; HIV-1; HUMANS; K562 CELLS; RIBONUCLEASE, PANCREATIC; RIBONUCLEASES; SUBSTRATE SPECIFICITY;

EID: 57049128294     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0146     Document Type: Article

References (53)

1. Hymes KB, Cheung T, Greene JB, et al.: Kaposi's sarcoma in homosexual men - a report of eight cases. Lancet 1981;2:598-600.
2. Carr A: Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov 2003;2:624-634.
3. Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, and Bolognesi D: Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 2004;3:215-225.
4. Hanson K and Hicks C: New antiretroviral drugs. Curr HIV/AIDS Rep 2006;3:93-101.
5. Barbaro G, Scozzafava A, Mastrolorenzo A, and Supuran CT: Highly active antiretroviral therapy: Current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005;11:1805-1843.
6. Temesgen Z, Warnke D, and Kasten MJ: Current status of antiretroviral therapy. Expert Opin Pharmacother 2006;7:1541-1554.
7. Kellerman S, Begley E, Boyett B, Clark H, and Schulden J: Changes in HIV and AIDS in the United States: Entering the third decade. Curr Infect Dis Rep 2005;7:138-143.
8. Weiss RA: HIV and AIDS: Looking ahead. Nat Med 2003;9:887-891.
9. Flexner C: HIV drug development: The next 25 years. Nat Rev Drug Discov 2007;6:959-966.
10. Agrawal L, Lu X, Jin Q, and Alkhatib G: Anti-HIV therapy: Current and future directions. Curr Pharm Des 2006;12:2031-2055.
11. Shafer RW: Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002;15:247-277.
12. Simon V and Ho DD: HIV-1 dynamics in vivo: Implications for therapy. Nat Rev Microbiol 2003;1:181-190.
13. Yang QE: Human immunodeficiency virus reservoir might be actively eradicated as residual malignant cells by cytotoxic chemotherapy. Med Hypotheses 2004;62:358-363.
14. Ravot E, Lisziewicz J, and Lori F: New uses for old drugs in HIV infection: The role of hydroxyurea, cyclosporin and thalidomide. Drugs 1999;58:953-963.
15. Kohl NE, Emini EA, Schleif WA, et al.: Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988;85:4686-4690.
16. Vocero-Akbani AM, Heyden NV, Lissy NA, Ratner L, and Dowdy SF: Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med 1999;5:29-33.
17. Falnes PO, Welker R, Krausslich HG, and Olsnes S: Toxins that are activated by HIV type-1 protease through removal of a signal for degradation by the N-end-rule pathway. Biochem J 1999;343(Pt 1):199-207.
18. Raines RT: Ribonuclease A. Chem Rev 1998;98:1045-1065.
19. Marshall GR, Feng JA, and Kuster DJ: Back to the future: Ribonuclease A. Biopolymers 2008;90:259-277.
20. D'Alessio G and Riordan JF, eds.: Ribonucleases: Structures and Functions. Academic Press, New York, 1997.
21. Matousek J: Ribonucleases and their antitumor activity. Comp Biochem Physiol 2001;129C:175-191.
22. Leland PA and Raines RT: Cancer chemotherapy - ribonucleases to the rescue. Chem Biol 2001;8:405-413.
23. Makarov AA and Ilinskaya ON: Cytotoxic ribonucleases: Molecular weapons and their targets. FEBS Lett 2003;540:15-20.
24. Benito A, Ribó M, and Vilanova M: On the track of antitumor ribonucleases. Mol Biosyst 2005;1:294-302.
25. Arnold U and Ulbrich-Hofmann R: Natural and engineered ribonucleases as potential cancer therapeutics. Biotechnol Lett 2006;28:1615-1622.
26. Lee JE and Raines RT: Ribonucleases as novel chemotherapeutics: The ranpirnase example. BioDrugs 2008;22:53-58.
27. Ardelt W, Mikulski SM, and Shogen K: Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. J Biol Chem 1991;266:245-251.
28. Pavlakis N and Vogelzang NJ: Ranpirnase - an antitumour ribonuclease: Its potential role in malignant mesothelioma. Expert Opin Biol Ther 2006;6:391-399.
29. Youle RJ, Wu YN, Mikulski SM, et al.: RNase inhibition of human immunodeficiency virus infection of H9 cells. Proc Natl Acad Sci USA 1994;91:6012-6106.
30. Bedoya VI, Boasso A, Hardy AW, Rybak S, Shearer GM, and Rugeles MT: Ribonucleases in HIV type 1 inhibition: Effect of recombinant RNases on infection of primary T cells and immune activation-induced RNase gene and protein expression. AIDS Res Hum Retroviruses 2006;22:897-907.
31. Plainkum P, Fuchs SM, Wiyakrutta S, and Raines RT: Creation of a zymogen. Nat Struct Biol 2003;10:115-119.
32. Johnson RJ, Lin SR, and Raines RT: A ribonuclease zymogen activated by the NS3 protease of the hepatitis C virus. FEBS J 2006;273:5457-5465.
33. Lozzio CB and Lozzio BB: Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975;45:321-334.
34. Ido E, Han HP, Kezdy FJ, and Tang J: Kinetic studies of human immunodeficiency virus type 1 protease and its activesite hydrogen bond mutant A28S. J Biol Chem 1991;266:24359-24366.
35. Kelemen BR, Klink TA, Behlke MA, Eubanks SR, Leland PA, and Raines RT: Hypersensitive substrate for ribonucleases. Nucleic Acids Res 1999;27:3696-3701.
36. Smith BD, Soellner MB, and Raines RT: Potent inhibition of ribonuclease A by oligo(vinylsulfonic acid). J Biol Chem 2003;278:20934-20938.
37. Mildner AM, Rothrock DJ, Leone JW, et al.: The HIV-1 protease as enzyme and substrate: Mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties. Biochemistry 1994;33:9405-9413.
38. Davis DA, Dorsey K, Wingfield PT, et al.: Regulation of HIV-1 protease activity through cysteine modification. Biochemistry 1996;35:2482-2488.
39. Pan SH and Malcolm BA: Reduced background expression and improved plasmid stability with pET vectors in BL21 (DE3). Biotechniques 2000;29:1234-1238.
40. Todd MJ, Semo N, and Freire E: The structural stability of the HIV-1 protease. J Mol Biol 1998;283:475-488.
41. a of fluorescein to optimize binding assays. Anal Chem 2007;79:6775-6782.
42. Rutkoski TJ, Kurten EL, Mitchell JC, and Raines RT: Disruption of shape-complementarity markers to create cytotoxic variants of ribonuclease A. J Mol Biol 2005;354:41-54.
43. Pettit SC, Moody MD, Wehbie RS, et al.: The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol 1994;68:8017-8027.
44. Pettit SC, Lindquist JN, Kaplan AH, and Swanstrom R: Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology 2005;2:66.
45. Klink TA and Raines RT: Conformational stability is a determinant of ribonuclease A cytotoxicity. J Biol Chem 2000;275:17463-17467.
46. Hui JO, Tomasselli AG, Zurcher-Neely HA, and Heinrikson RL: Ribonuclease A as a substrate of the protease from human immunodeficiency virus-1. J Biol Chem 1990;265:21386-21389.
47. Suhasini AN and Sirdeshmukh R: Transfer RNA cleavages by onconase reveal unusual cleavage sites. J Biol Chem 2006;281:12201-12209.
48. Leland PA, Schultz LW, Kim B-M, and Raines RT: Ribonuclease A variants with potent cytotoxic activity. Proc Natl Acad Sci USA 1998;98:10407-10412.
49. Rutkoski TJ and Raines RT: Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity. Curr Pharm Biotechnol 2008;9:185-199.
50. Kobe B and Deisenhofer J: Mechanism of ribonuclease inhibition by ribonuclease inhibitor protein based on the crystal structure of its complex with ribonuclease A. J Mol Biol 1996;264:1028-1043.
51. Johnson RJ, McCoy JG, Bingman CA, Phillips GN Jr, and Raines RT: Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein. J Mol Biol 2007;367:434-449.
52. Bjellqvist B, Basse B, Olsen E, and Celis JE: Reference points for comparisons of two-dimensional maps of proteins from different human cell types defined in a pH scale where isoelectric points correlate with polypeptide compositions. Electrophoresis 1994;15:529-539.
53. Lee FS, Shapiro R, and Vallee BL: Tight-binding inhibition of angiogenin and ribonuclease A by placental ribonuclease inhibitor. Biochemistry 1989;28:225-230.